TuHURA Biosciences Received FDA Orphan Drug Designation for IFx-2.0 for the Treatment of Stage IIB To Stage IV Cutaneous Melanoma (TuHURA Biosciences)
TuHURA Biosciences, formed by CohBar and Morphogenesis, a UF startup, announced that the U.S FDA has granted Orphan Drug Designation (ODD) to IFx-2.0 for the treatment of stage IIB to stage IV cutaneous melanoma.
TuHURA Biosciences Initiates Its Phase 3 Accelerated Approval Trial of IFx-2.0 as an Adjunctive Therapy to Keytruda® (Pembrolizumab) in First Line Treatment for Advanced or Metastatic Merkel Cell Carcinoma
TuHURA Biosciences, formed by CohBar and Morphogenesis, a UF startup, has announced the initiation of its Phase 3 accelerated approval trial of IFx-2.0, TuHURA’s lead innate immune agonist, in patients with advanced or metastatic Merkel cell carcinoma (MCC).